Zacks Research Begins Coverage on Harvard Bioscience (NASDAQ:HBIO)

Investment analysts at Zacks Research initiated coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a report released on Tuesday, Zacks reports. The firm set a “hold” rating on the medical instruments supplier’s stock.

Other research analysts have also recently issued reports about the stock. Benchmark increased their price target on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a report on Wednesday, August 12th. Weiss Ratings cut Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.75.

Harvard Bioscience Stock Down 0.7%

HBIO stock opened at $8.61 on Tuesday. Harvard Bioscience has a 1-year low of $4.00 and a 1-year high of $9.10. The business’s 50 day simple moving average is $8.19 and its 200 day simple moving average is $6.47. The company has a current ratio of 1.87, a quick ratio of 0.98 and a debt-to-equity ratio of 4.94. The firm has a market capitalization of $39.18 million, a PE ratio of -3.73 and a beta of 1.47.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. The firm had revenue of $22.73 million for the quarter, compared to the consensus estimate of $21.45 million. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. As a group, research analysts anticipate that Harvard Bioscience will post -2.44 EPS for the current year.

Hedge Funds Weigh In On Harvard Bioscience

An institutional investor recently bought a new position in Harvard Bioscience stock. Citadel Advisors LLC purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned approximately 0.29% of Harvard Bioscience as of its most recent SEC filing. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience News Summary

Here are the key news stories impacting Harvard Bioscience this week:

• Neutral Sentiment: Sidoti forecasts a gradual improvement, with estimated losses of $2.44 per share in 2026 and $1.15 in 2027, followed by positive EPS of $0.43 in 2028. The outlook suggests a potential longer-term recovery, but the articles do not indicate that these estimates were revisions. MarketBeat Harvard Bioscience coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost are scheduled to participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. No new financial or operating information was disclosed in the announcement. Forum participation announcement

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.